Fibrin-derived Peptide as Salvage Treatment in Critically Ill Patients with COVID-19-associated ARDS

ccforum.biomedcentral.com September 24, 2020

fibrin-derived-peptide-bβ15-42-fx06-as-salvage-treatment-in-critically-ill-patients-with-covid-19-associated-acute-respiratory-distress-syndrome

After SARS-CoV-2 first occurred in China in December of 2019, it set out to become a global pandemic. Critically ill patients constitute about 2–9% of all infected patients and progress from pneumonia and hypoxemia to multi-organ dysfunction, for which acute treatment options are scarce.

Currently, there is no clinical evidence supporting the efficacy and safety of a drug against any coronavirus in humans, including SARS-CoV-2.

Here, we describe the empirical salvage treatment of critically ill COVID-19 patients in two German tertiary care University Hospitals with FX06 (F4 Pharma, Vienna, Austria), a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bβ15-42).

FX06 is known for its immunomodulatory properties and was already investigated in clinical trials demonstrating convincing efficacy while being tolerated well with a favorable safety profile.

This observational case series includes six patients during their treatment in the ICU.